Material Event Form 8 K

Item 8.01. Other Events.

As previously disclosed, on May 22, 2024, the Nasdaq Listing Qualifications department ("Nasdaq") informed Protagenic Therapeutics, Inc. (the "Company") that it did not meet the minimum $2,500,000 stockholders' equity requirement for continued listing as set forth in Nasdaq Listing Rule 5550(b)(1) (the "Rule").

Nasdaq initially provided the Company until July 8, 2024, to submit a plan to regain compliance. The Company submitted its compliance plan on time, and Nasdaq subsequently granted an extension to allow the Company to meet the requirements of the Rule.

While the Company made efforts to address the compliance requirements during the extension period, it was unable to meet the necessary stockholders' equity threshold by November 18, 2024. Consequently, on November 19, 2024, Nasdaq issued a determination letter (the "Nasdaq Determination Letter") notifying the Company of its non-compliance with the terms of the extension.

On November 27, 2024, the Company appealed the Nasdaq Determination Letter and requested a hearing (the "Hearing") before the Nasdaq Hearings Panel (the "Panel"). On November 29, 2024, Nasdaq informed the Company that the delisting action has been stayed, pending a final written decision by the Panel. The Hearing is scheduled for January 30, 2025, and the deadline for submission of materials to the Panel is January 10, 2025. Nasdaq also provided detailed instructions regarding the Hearing process.

The Company is committed to working diligently to present a comprehensive plan to the Panel aimed at regaining compliance with the Rule. While the Company remains focused on achieving this objective, there can be no assurance that the Panel will grant the Company additional time to regain compliance or that the Company will meet all applicable requirements for continued listing on The Nasdaq Capital Market.